U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of the Commissioner
  5. Office of the Chief Scientist
  6. Guidance Documents by the Office of the Chief Scientist
  7. Office of the Chief Scientist Guidance Documents Under Development
  1. Guidance Documents by the Office of the Chief Scientist

Office of the Chief Scientist Guidance Documents Under Development

Expected to publish as draft guidance or final guidance by the end of December 2025.

 

Introduction

The following list of guidance topics includes possible new topics for guidance documents and/or revisions to existing guidance documents that the Office of the Chief Scientist is considering. We currently intend to develop guidance on each topic; however, the Office of the Chief Scientist is neither bound by this list of topics, nor required to issue every guidance document on this list. Several factors may impact FDA’s ability to issue a guidance, including, for example, new Administration priorities, emerging public health issues, or other extenuating circumstances. We may also issue guidance documents on topics not on this list.

You may submit comments on the guidance topics at www.regulations.gov at Docket FDA-2023-N-5020.

Guidance Document Table

Guidance TopicCategory
Mandatory Recalls*Cosmetics
Records Access*Cosmetics
Conflicts of Interest and Eligibility for Participation in FDA Advisory CommitteesAdvisory Committee
Appearance Concerns and Authorizations for Participation in FDA Advisory CommitteesAdvisory Committee

* Indicates guidance developed by FDA/OII in collaboration with OCS.

Good Guidance Practices

Back to Top